Brexit: A Serious Threat to Patients
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
Address: Bristol-Myers Squibb Pharmaceuticals Limited (Uxbridge), MS House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH, United Kingdom
Tel: +44 (0)1895 523000
Since 1858, medicines made by Bristol-Myers Squibb have helped millions of patients around the world fight serious diseases such as cancer, heart disease, diabetes, HIV/AIDS, chronic hepatitis B, rheumatoid arthritis and various psychiatric disorders.
From those early days, the company has been developing our offering to better meet the needs of patients. By combining the best elements of a leading-edge biotech company with the resources of a major pharmaceutical company, BMS is transforming into a new kind of enterprise: a next-generation BioPharma leader.
At the heart of this BioPharma strategy are the medicines that give meaningful hope to patients and physicians and bring value to its shareholders and customers. Since 2002, BMS introduced eight new products for the treatment of numerous serious diseases.
As well as all these products now on the market, scores of additional investigational medicines are advancing through the company’s pharmaceutical development pipeline. In fact, Bristol-Myers Squibb is recognised as having one of the most productive pipelines in the industry.
Over the years, Bristol-Myers Squibb and its employees have received awards and recognition. We have been listed as one of the best companies to work for by The Sunday Times. We have also been acknowledged as an industry leader in environment, health and safety management.
Finally, our philanthropic programmes have given new hope to some of the world’s most vulnerable citizens.
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug…
Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how…
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Recently appointed CEO of Health Innovation Manchester, Ben Bridgewater explains the organization’s goal of improving the lives of the people of Greater Manchester by ensuring a constant pipeline of innovation,…
Taking the conversation beyond Brexit, His Excellency Lars Thuesen, ambassador of Denmark to the UK, highlights the solid ties that have linked both countries since the Danes invaded the island…
The Ambassador of Switzerland to the UK, Alexandre Fasel, discloses what has been achieved so far with the ‘Mind the Gap’ strategy, aimed at safeguarding British-Swiss economic and business…
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back…
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short…
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and…
See our Cookie Privacy Policy Here
